PT - JOURNAL ARTICLE AU - Singh, Romil AU - Rathore, Sawai Singh AU - Khan, Hira AU - Bhurwal, Abhishek AU - Sheraton, Mack AU - Ghosh, Prithwish AU - Anand, Sohini AU - Makadia, Janaki AU - Ayesha, FNU AU - Mahapure, Kiran S. AU - Mehra, Ishita AU - Tekin, Aysun AU - Kashyap, Rahul AU - Bansal, Vikas TI - Mortality and Severity in COVID-19 Patients on ACEIs & ARBs - A Meta-Regression Analysis AID - 10.1101/2021.03.14.21253557 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.14.21253557 4099 - http://medrxiv.org/content/early/2021/03/24/2021.03.14.21253557.short 4100 - http://medrxiv.org/content/early/2021/03/24/2021.03.14.21253557.full AB - Purpose The primary objective of this review is to examine studies reporting association of mortality in COVID-19 patients with whether they were on Angiotensin-converting-enzyme inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs). A secondary objective is to similarly access associations with higher severity of the disease in COVID-19 patients.Materials and Methods We searched multiple COVID-19 databases (WHO, CDC, LIT-COVID) for randomized trials and longitudinal studies from all over the world reporting mortality and severity published before January 18th, 2021. Meta-analyses were performed using 53 studies for mortality outcome and 43 for the severity outcome. Mantel-Haenszel odds ratios were generated to describe overall effect size using random effect models. To account for between study results variations, multivariate meta-Regression was performed with preselected covariates using maximum likelihood method for both the mortality and severity models.Result Our findings showed that the use of ACEIs/ARBs did not significantly influence either mortality (OR=1.16 95% CI 0.94 to 1.44, p= 0.15, I2 = 93.2%) or severity (OR=1.18, 95% CI 0.94 to 1.48 p= 0.15, I2 = 91.1%) in comparison to not being on ACEIs/ARBs in COVID-19 positive patients. Multivariate meta-regression for the mortality model demonstrated that 36% of between study variations could be explained by differences in age, gender, and proportion of heart diseases in the study samples. Multivariate meta-regression for the severity model demonstrated that 8% of between study variations could be explained by differences in age, proportion of diabetes, heart disease and study country in the study samples.Conclusion We found no association of mortality or severity in COVID-19 patients taking ACEIs/ARBs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe did not receive any funding for this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was a meta-analysis study, did not require IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe performed a meta-analysis from already published literature (preprint and peer-reviewed).